Interstitial Lung Disease and Lung Transplantation

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias and carries the worst prognosis. Currently the best treatment option is lung transplantation. Historically patients with IPF had poor outcomes following referral for lung transplant due to high waiting-list mortality. The introduction of the lung allocation score in the United States in 2005 has reduced 1 year waiting-list mortality from 21% to 11% and also led to IPF becoming the most common diagnosis for lung transplantation. Although prioritizing all patients with IPF on the waiting list has led to a dramatic decline in waiting-list mortality, further improvements may be made by prioritizing which patients with IPF should be transplanted, with an emphasis on 6-minute walk testing, biomarkers, and the presence of pulmonary hypertension rather than traditional pulmonary function tests. The choice of surgical procedure and the prediction and management of posttransplant complications may also influence long-term outcomes.

KEYWORDS

Lung - fibrosis - transplant

REFERENCES

• 1 Table 12.4a Transplant Recipient Characteristics, 1998 to 2007 Recipients of Deceased Donor Lungs. 2008 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998–2007. In: Organ Procurement and Transplantation Network; 2008 http://optn.transplant.hrsa.gov/ar2008/Chapter_VI_AR_CD.htm?cp=7#14
• 2 American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias . This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.  Am J Respir Crit Care Med. 2002;  165(2) 277-304
• 3 Bjoraker J A, Ryu J H, Edwin M K et al.. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1998;  157 199-203
• 4 du Bois R, King Jr T E. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.  Thorax. 2007;  62 1008-1012
• 5 Thabut G, Mal H, Castier Y et al.. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis.  J Thorac Cardiovasc Surg. 2003;  126 469-475
• 6 Chen H, Shiboski S C, Golden J A et al.. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2009;  180 468-474
• 7 Haider Y, Yonan N, Mogulkoc N, Carroll K B, Egan J J. Bronchiolitis obliterans syndrome in single lung transplant recipients—patients with emphysema versus patients with idiopathic pulmonary fibrosis.  J Heart Lung Transplant. 2002;  21 327-333
• 8 Orens J B, Estenne M, Arcasoy S Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.  J Heart Lung Transplant. 2006;  25 745-755
• 9 Collard H R, King Jr T E, Bartelson B B, Vourlekis J S, Schwarz M I, Brown K K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2003;  168 538-542
• 10 Flaherty K R, Mumford J A, Murray S et al.. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.  Am J Respir Crit Care Med. 2003;  168 543-548
• 11 King Jr T E, Safrin S, Starko K M et al.. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.  Chest. 2005;  127 171-177
• 12 Lederer D J, Arcasoy S M, Wilt J S, D'Ovidio F, Sonett J R, Kawut S M. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2006;  174 659-664
• 13 Lama V N, Flaherty K R, Toews G B et al.. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.  Am J Respir Crit Care Med. 2003;  168 1084-1090
• 14 Boon K, Bailey N W, Yang J et al.. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).  PLoS One. 2009;  4 e5134
• 15 Rosas I O, Richards T J, Konishi K et al.. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.  PLoS Med. 2008;  5 e93
• 16 Prasse A, Probst C, Bargagli E et al.. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 2009;  179 717-723
• 17 Kinder B W, Brown K K, McCormack F X et al.. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.  Chest. 2009;  135 1557-1563
• 18 Meyers B F, Lynch J P, Trulock E P, Guthrie T, Cooper J D, Patterson G A. Single versus bilateral lung transplantation for idiopathic pulmonary fibrosis: a ten-year institutional experience.  J Thorac Cardiovasc Surg. 2000;  120 99-107
• 19 Charman S C, Sharples L D, McNeil K D, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis.  J Heart Lung Transplant. 2002;  21 226-232
• 20 Meyer D M, Edwards L B, Torres F, Jessen M E, Novick R J. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis.  Ann Thorac Surg. 2005;  79 950-957, discussion 957–958
• 21 Nwakanma L U, Simpkins C E, Williams J A et al.. Impact of bilateral versus single lung transplantation on survival in recipients 60 years of age and older: analysis of United Network for Organ Sharing database.  J Thorac Cardiovasc Surg. 2007;  133 541-547
• 22 Keating D, Levvey B, Kotsimbos T et al.. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years.  Transplant Proc. 2009;  41 289-291
• 23 Weiss E S, Allen J G, Merlo C A, Conte J V, Shah A S. Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis.  Ann Thorac Surg. 2009;  88 1616-1625 discussion 1625-1626
• 24 Lettieri C J, Nathan S D, Barnett S D, Ahmad S, Shorr A F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.  Chest. 2006;  129 746-752
• 25 Arcasoy S M, Christie J D, Ferrari V A et al.. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.  Am J Respir Crit Care Med. 2003;  167 735-740
• 26 Nadrous H F, Pellikka P A, Krowka M J et al.. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.  Chest. 2005;  128 2393-2399
• 27 Zisman D A, Lynch III J P, Strieter R M et al.. Pulmonary arterial hypertension (PAH) is common in patients with idiopathic pulmonary fibrosis referred for lung transplantation [abstract].  Am J Respir Crit Care Med. 2005;  2 A123
• 28 Gagermeier J, Dauber J H, Gibson K, Richards T, Kaminski N. Prevalence of secondary pulmonary hypertension in patients with idiopathic pulmonary fibrosis [abstract].  Proc Am Thorac Soc. 2005;  2 A205
• 29 Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases.  Respiration. 1983;  44 118-127
• 30 Shorr A F, Cors C, Lettieri C J, Nathan S. Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology and clinical correlates.  Chest. 2005;  128S 218S
• 31 Kawut S M, O'Shea M K, Bartels M N, Wilt J S, Sonett J R, Arcasoy S M. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation.  Respir Med. 2005;  99 1431-1439
• 32 Lederer D J, Caplan-Shaw C E, O'Shea M K et al.. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis.  Am J Transplant. 2006;  6 398-403
• 33 Hamada K, Nagai S, Tanaka S et al.. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis.  Chest. 2007;  131(3) 650-656
• 34 King Jr T E, Tooze J A, Schwarz M I, Brown K R, Cherniack R M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.  Am J Respir Crit Care Med. 2001;  164(7) 1171-1181
• 35 Whelan T P, Dunitz J M, Kelly R F et al.. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis.  J Heart Lung Transplant. 2005;  24 1269-1274
• 36 Whitson B A, Nath D S, Johnson A C et al.. Risk factors for primary graft dysfunction after lung transplantation.  J Thorac Cardiovasc Surg. 2006;  131 73-80
• 37 Bando K, Keenan R J, Paradis I L et al.. Impact of pulmonary hypertension on outcome after single-lung transplantation.  Ann Thorac Surg. 1994;  58 1336-1342
• 38 Daud S A, Yusen R D, Meyers B F et al.. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome.  Am J Respir Crit Care Med. 2007;  175 507-513
• 39 Arcasoy S M, Fisher A, Hachem R R, Scavuzzo M, Ware L B. ISHLT Working Group on Primary Lung Graft Dysfunction . Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, V: Predictors and outcomes.  J Heart Lung Transplant. 2005;  24 1483-1488
• 40 Kozower B D, Meyers B F, Smith M A et al.. The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study.  J Thorac Cardiovasc Surg. 2008;  135 166-171
• 41 Meyer D M, Bennett L E, Novick R J, Hosenpud J D. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation.  Chest. 2000;  118 1255-1262
• 42 de Perrot M, Bonser R S, Dark J ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, III: Donor-related risk factors and markers.  J Heart Lung Transplant. 2005;  24 1460-1467
• 43 Lee J, Kuntz C L, Hadjiliadis D et al.. Risk factors for primary graft dysfunction after lung transplantation [abstract].  Am J Respir Crit Care Med. 2008;  177 A396
• 44 Fiser S M, Kron I L, McLendon Long S, Kaza A K, Kern J A, Tribble C G. Early intervention after severe oxygenation index elevation improves survival following lung transplantation.  J Heart Lung Transplant. 2001;  20 631-636
• 45 Barr M L, Kawut S M, Whelan T P ISHLT Working Group on Primary Lung Graft Dysfunction et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, IV: Recipient-related risk factors and markers.  J Heart Lung Transplant. 2005;  24 1468-1482
• 46 Bobadilla J L, Love R B, Jankowska-Gan E et al.. Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation.  Am J Respir Crit Care Med. 2008;  177 660-668
• 47 Nathan S D, Barnett S D, Urban B A, Nowalk C, Moran B R, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients.  Chest. 2003;  123 1758-1763
• 48 Kelly K, Hertz M I. Obliterative bronchiolitis.  Clin Chest Med. 1997;  18 319-338
• 49 Stewart S, Fishbein M C, Snell G I et al.. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection.  J Heart Lung Transplant. 2007;  26 1229-1242
• 50 Estenne M, Maurer J R, Boehler A et al.. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria.  J Heart Lung Transplant. 2002;  21 297-310
• 51 Burton C M, Carlsen J, Mortensen J, Andersen C B, Milman N, Iversen M. Long-term survival after lung transplantation depends on development and severity of bronchiolitis obliterans syndrome.  J Heart Lung Transplant. 2007;  26 681-686
• 52 El-Gamel A, Awad M R, Hasleton P S et al.. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis.  J Heart Lung Transplant. 1999;  18 517-523
• 53 El-Gamel A, Sim E, Hasleton P et al.. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation.  J Heart Lung Transplant. 1999;  18 828-837
• 54 Snyder L D, Hartwig M G, Ganous T et al.. Cytokine gene polymorphisms are not associated with bronchiolitis obliterans syndrome or survival after lung transplant.  J Heart Lung Transplant. 2006;  25 1330-1335
• 55 Hodge S, Holmes M, Banerjee B et al.. Posttransplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition.  Am J Transplant. 2009;  9 727-733